Catalyst calendar
The repricing schedule is mostly public if you actually look at it.
AllI · Sterile fill-finish capacityII · Stoppers, syringes & drug-contact componentsIII · Pharmaceutical glass & vialsIV · Bioprocessing consumables & resinsV · API & small-molecule reshoringVI · CDMO capacity & the China exodusVII · Peptide & oligonucleotide manufacturingVIII · Sterile injectables & shortage economicsIX · Analytical instruments & QC releaseX · Private giants & exposure vehicles
July 2026
- 30mediumEarningsBAXBaxter International Q2 2026 earnings (estimated late July/early August)Updates North Cove IV-fluid recovery and whether demand is still 10-15% below pre-Helene levels — the single most concentrated node in the chokepoint.
August 2026
- 06mediumEarningsAMPHAmphastar Pharmaceuticals Q2 2026 earningsReads US domestic sterile-injectable and emergency-drug demand and any shortage-driven pricing in naloxone/glucagon and legacy injectables.
- 13mediumEarningsHKMPYHikma Pharmaceuticals H1 2026 interim results (estimated, mirrors early-August 2025 timing)Tests the low-single-digit 2026 Injectables guidance and progress toward Bedford, OH commercial capacity coming online in 2028.
January 2027
- 15highPolicyGDUFA IV negotiated agreement statutory submission deadline to CongressGDUFA IV (FY2028-2032) explicitly weighs onshoring and domestic-production incentives that shape whether US sterile-injectable capacity gets built; the agreement must reach Congress by this date.